Exact Mass: 583.2126
Exact Mass Matches: 583.2126
Found 295 metabolites which its exact mass value is equals to given mass value 583.2126
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Brigatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
N-succinyl-chitosan
Pyripyropene A
ITX-5061 free base
Anthelmycin
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
4-amino-1-[4-amino-O2-(3-amino-beta-D-3-deoxy-glucopyranosyl)-beta-D-glycero-D-galacto-D-gluco-4-deoxy-undecopyranosyl]-1H-pyrimidin-2-one|Hikizimycin
Cys Glu Phe Trp
Cys Glu Trp Phe
Cys Phe Glu Trp
Cys Phe Trp Glu
Cys Ile Trp Tyr
Cys Ile Tyr Trp
Cys Leu Trp Tyr
Cys Leu Tyr Trp
Cys Trp Glu Phe
Cys Trp Phe Glu
Cys Trp Ile Tyr
Cys Trp Leu Tyr
Cys Trp Tyr Ile
Cys Trp Tyr Leu
Cys Tyr Ile Trp
Cys Tyr Leu Trp
Cys Tyr Trp Ile
Cys Tyr Trp Leu
Asp Met Arg Tyr
Asp Met Tyr Arg
Asp Arg Met Tyr
Asp Arg Tyr Met
Asp Thr Trp Tyr
Asp Thr Tyr Trp
Asp Trp Thr Tyr
Asp Trp Tyr Thr
Asp Tyr Met Arg
Asp Tyr Arg Met
Asp Tyr Thr Trp
Asp Tyr Trp Thr
Glu Cys Phe Trp
Glu Cys Trp Phe
Glu Phe Cys Trp
Glu Phe Trp Cys
Glu Ser Trp Tyr
Glu Ser Tyr Trp
Glu Trp Cys Phe
Glu Trp Phe Cys
Glu Trp Ser Tyr
Glu Trp Tyr Ser
Glu Tyr Ser Trp
Glu Tyr Trp Ser
Phe Cys Glu Trp
Phe Cys Trp Glu
Phe Glu Cys Trp
Phe Glu Trp Cys
Phe Met Met Arg
Phe Met Arg Met
Phe Met Thr Trp
Phe Met Trp Thr
Phe Arg Met Met
Phe Thr Met Trp
Phe Thr Trp Met
Phe Trp Cys Glu
Phe Trp Glu Cys
Phe Trp Met Thr
Phe Trp Thr Met
His His Gln Tyr
His His Tyr Gln
His Asn Gln Trp
His Asn Trp Gln
His Gln His Tyr
His Gln Asn Trp
His Gln Trp Asn
His Gln Tyr His
His Trp Asn Gln
His Trp Gln Asn
His Tyr His Gln
His Tyr Gln His
Ile Cys Trp Tyr
Ile Cys Tyr Trp
Ile Trp Cys Tyr
Ile Trp Tyr Cys
Ile Tyr Cys Trp
Ile Tyr Trp Cys
Leu Cys Trp Tyr
Leu Cys Tyr Trp
Leu Trp Cys Tyr
Leu Trp Tyr Cys
Leu Tyr Cys Trp
Leu Tyr Trp Cys
Met Asp Arg Tyr
Met Asp Tyr Arg
Met Phe Met Arg
Met Phe Arg Met
Met Phe Thr Trp
Met Phe Trp Thr
Met Met Phe Arg
Met Met Arg Phe
Met Arg Asp Tyr
Met Arg Phe Met
Met Arg Met Phe
Met Arg Tyr Asp
Met Thr Phe Trp
Met Thr Trp Phe
Met Trp Phe Thr
Met Trp Thr Phe
Met Tyr Asp Arg
Met Tyr Arg Asp
Asn His Gln Trp
Asn His Trp Gln
Asn Gln His Trp
Asn Gln Trp His
Asn Trp His Gln
Asn Trp Gln His
Gln His His Tyr
Gln His Asn Trp
Gln His Trp Asn
Gln His Tyr His
Gln Asn His Trp
Gln Asn Trp His
Gln Trp His Asn
Gln Trp Asn His
Gln Tyr His His
Arg Asp Met Tyr
Arg Asp Tyr Met
Arg Phe Met Met
Arg Met Asp Tyr
Arg Met Phe Met
Arg Met Met Phe
Arg Met Tyr Asp
Arg Tyr Asp Met
Arg Tyr Met Asp
Ser Glu Trp Tyr
Ser Glu Tyr Trp
Ser Trp Glu Tyr
Ser Trp Tyr Glu
Ser Tyr Glu Trp
Ser Tyr Trp Glu
Thr Asp Trp Tyr
Thr Asp Tyr Trp
Thr Phe Met Trp
Thr Phe Trp Met
Thr Met Phe Trp
Thr Met Trp Phe
Thr Trp Asp Tyr
Thr Trp Phe Met
Thr Trp Met Phe
Thr Trp Tyr Asp
Thr Tyr Asp Trp
Thr Tyr Trp Asp
Trp Cys Glu Phe
Trp Cys Phe Glu
Trp Cys Ile Tyr
Trp Cys Leu Tyr
Trp Cys Tyr Ile
Trp Cys Tyr Leu
Trp Asp Thr Tyr
Trp Asp Tyr Thr
Trp Glu Cys Phe
Trp Glu Phe Cys
Trp Glu Ser Tyr
Trp Glu Tyr Ser
Trp Phe Cys Glu
Trp Phe Glu Cys
Trp Phe Met Thr
Trp Phe Thr Met
Trp His Asn Gln
Trp His Gln Asn
Trp Ile Cys Tyr
Trp Ile Tyr Cys
Trp Leu Cys Tyr
Trp Leu Tyr Cys
Trp Met Phe Thr
Trp Met Thr Phe
Trp Asn His Gln
Trp Asn Gln His
Trp Gln His Asn
Trp Gln Asn His
Trp Ser Glu Tyr
Trp Ser Tyr Glu
Trp Thr Asp Tyr
Trp Thr Phe Met
Trp Thr Met Phe
Trp Thr Tyr Asp
Trp Tyr Cys Ile
Trp Tyr Cys Leu
Trp Tyr Asp Thr
Trp Tyr Glu Ser
Trp Tyr Ile Cys
Trp Tyr Leu Cys
Trp Tyr Ser Glu
Trp Tyr Thr Asp
Tyr Cys Ile Trp
Tyr Cys Leu Trp
Tyr Cys Trp Ile
Tyr Cys Trp Leu
Tyr Asp Met Arg
Tyr Asp Arg Met
Tyr Asp Thr Trp
Tyr Asp Trp Thr
Tyr Glu Ser Trp
Tyr Glu Trp Ser
Tyr His His Gln
Tyr His Gln His
Tyr Ile Cys Trp
Tyr Ile Trp Cys
Tyr Leu Cys Trp
Tyr Leu Trp Cys
Tyr Met Asp Arg
Tyr Met Arg Asp
Tyr Gln His His
Tyr Arg Asp Met
Tyr Arg Met Asp
Tyr Ser Glu Trp
Tyr Ser Trp Glu
Tyr Thr Asp Trp
Tyr Thr Trp Asp
Tyr Trp Cys Ile
Tyr Trp Cys Leu
Tyr Trp Asp Thr
Tyr Trp Glu Ser
Tyr Trp Ile Cys
Tyr Trp Leu Cys
Tyr Trp Ser Glu
Tyr Trp Thr Asp
(3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate
Nilotinib hydrochloride monohydrate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor
Pyripyropene A
A sesquiterpenoid that consists of (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diol in which the hydrogens of the 3- and 6-hydroxy functions are substituted by acetyl groups.
methyl (phenyl 5-acetamido-4,7,8,9-tetra-o-acetyl-3,5-dideoxy-2-thio-d-glycero-d-galacto-2-nonulopyranosid)onate
4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1- piperazinecarboxylic acid 1,1-dimethylethyl ester
Methyl 2-[(2-methylpyridin-4-yl)methyl]-1-oxo-8-(pyrimidin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-1,2-dihydro-2,7-naphthyridine-3-carboxylate
Brigatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-gammaGlu-L-gammaGlu-OH
1-[5-[3-Amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]pyrrolidine-2,5-dione
N-[(2R,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
2-[(2R,4aS,12aS)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
2-[(2S,4aS,12aR)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2R,4aS,12aR)-8-[(4-chlorophenyl)carbamoylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-piperidin-1-ylethyl)acetamide
N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
2-[(2S,4aR,12aS)-8-[(4-chlorophenyl)carbamoylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-piperidin-1-ylethyl)acetamide
2-[(2S,4aR,12aR)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
N-[(2R,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
2-[(2S,4aS,12aS)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(3-methoxyphenyl)-1-methylurea
2-[(2R,4aR,12aR)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2R,4aR,12aS)-8-[[(4-chloroanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
Antelmycin
A nucleoside antibiotic with anthelminthic properties that is isolated from Streptomyces longissimus.
12-ethyl-8-propyl-3-vinylbacteriochlorophyllide d(1-)
A cyclic tetrapyrrole anion that is the conjugate base of 12-ethyl-8-propyl-3-vinylbacteriochlorophyllide d, obtained by deprotonation of the carboxy group; major species at pH 7.3.
ASTX029
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC50: 2.7 nM). ASTX029 has anti-cancer activity[1][2].
AZD-8529 (mesylate)
AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes[1].